Passive Immunization with Phospho-Tau Antibodies Reduces Tau Pathology and Functional Deficits in Two Distinct Mouse Tauopathy Models
PLOS One; DOI: 10.1371/journal.pone.0125614
C-terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer's disease
The Journal of the Alzheimer’s Association; doi.org/10.1016/j.jalz.2015.05.012.
Effects of antibodies to phosphorylated and non-phosphorylated tau on in vitro tau phosphorylation at Serine-199: Preliminary report.
ScienceDirect; doi:10.1016/j.exger.2015.04.010.
Brain-derived neurotrophic factor and TrkB expression in the “oldest-old,” the 90+ Study: correlation with cognitive status and levels of soluble amyloid-beta.
ScienceDirect; doi:10.1016/j.neurobiolaging.2015.08.022.
A novel tau mutation, p.K317N, causes globular glial tauopathy
Acta Neuropathologica; doi:10.1007/s00401-015-1425-0
QUANTIFICATION OF TAU IN BIOLOGICAL SAMPLES BY IMMUNOAFFINITY ENRICHMENT AND MASS SPECTROMETRY.
Free Patents Online; http://www.freepatentsonline.com/y2015/0253341.html.
HUMAN ANTI-TAU ANTIBODIES.
Free Patents Online; http://www.freepatentsonline.com/y2015/0252102.html.
Identification and characterization of natural antibodies against tau protein in an intravenous immunoglobulin product.
Science Direct; doi:10.1016/j.jneuroim.2015.10.017.
Depletion of microglia and inhibition of exosome synthesis halt tau propagation
Nature Neuroscience; doi:10.1038/nn.4132.
Phenolic compounds prevent the oligomerization of α-synuclein and reduce synaptic toxicity.
JNC Journal of Neurochemistry; DOI: 10.1111/jnc.13180.